Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet

 44

 TERMINÉ 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet

 34

 TERMINÉ 

Labeling of Enalapril from Neonates up to Adolescents (LENA)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Children are often treated as small adults—not as the special patients they are. Regulations exist to encourage the development of drugs and formulation for children. However, off-patent drugs are often administered to children without appropriate formulations or systematic investigations. Therefore, the paediatric use marketing authorisation (PUMA) has been designed.The EMA Paediatric Working Par ...
Voir le projet

 14

 TERMINÉ 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Voir le projet

 20

 TERMINÉ 

Personalised Prognostic Tools for Early Psychosis Management (PRONIA)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Affective and non-affective psychoses have a major negative impact on human society. They account for 6.3% of the global burden of disease and cost €207 billion per year in Europe alone, making them the most expensive brain-related disorders and even more expensive than cardiovascular diseases. This socioeconomic burden is largely caused by two core disease features: onset in adolescence and early ...
Voir le projet

 13

 TERMINÉ 

MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy (EPIMIRNA)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling p ...
Voir le projet

 19

 TERMINÉ 

New approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine (HYPORTH)

Date du début: 1 août 2013, Date de fin: 31 juil. 2018,

Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic risk implied by this burden could be addressed by efforts to achieve an increase in Healthy Life Years. One key element would be to ensure unrestricted mobility for especially the elderly, allowing them to stay at work for longer. Irreversible joint deterioration ...
Voir le projet

 11

 TERMINÉ 

Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing (FEMNAT-CD)

Date du début: 1 sept. 2013, Date de fin: 28 févr. 2018,

Conduct Disorder (CD) and Oppositional Defiant Disorder with symptoms of Conduct Disorder (which is included among the abbreviation “CD” throughout the proposal) has a highly negative impact for the affected individual as well as for families and society. Although the number of females exhibiting serious aggressive behaviours is growing, the majority of studies on aetiology and treatment of CD hav ...
Voir le projet

 19

 TERMINÉ 

Bioactivated hierarchical hydrogels as zonal implants for articular cartilage regeneration (HYDROZONES)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Degeneration of cartilage is a major cause of chronic pain, lost mobility and reduced quality of life for millions of European citizens. From a clinical point of view treatment to achieve cartilage regeneration (hyaline) and not only repair (fibrous) remains a great challenge. No clinical therapy is available that leads to healing of cartilage defects.Current cartilage implants cannot establish th ...
Voir le projet

 18

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,

WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Voir le projet

 13

 TERMINÉ 

Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,

Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillat ...
Voir le projet

 13

 TERMINÉ 

Emerging mental health systems in low- and middle-income countries (EMERALD)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

The objective of the EMERALD Project is to improve mental health outcomes by enhancing health system performance.The key issues addressed are: (i) adequate, fair & sustainable resourcing: using human, infrastructural, informational & financial resource inputs to effectively deliver better mental health services; (ii) integrated service provision: enhancing access to integrated community care; and ...
Voir le projet

 12

 TERMINÉ 

Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)

Date du début: 1 oct. 2010, Date de fin: 30 sept. 2017,

Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Voir le projet

 17

 TERMINÉ 

European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet

 29

 TERMINÉ 

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope (EU-CERT-ICD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have dramatically increased in recent years leading to multi-billion Euros of costs with significant regional disparities across Europe. Information on risks, benefits and cos ...
Voir le projet

 27

 TERMINÉ 

Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons (SENATOR)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

The European population of older people with multiple chronic diseases (multimorbidity) is increasing steadily in tandem with the rising population of people aged ≥ 65 years. Older multimorbid people are at high risk of polypharmacy (PP), inappropriate prescribing (IP), adverse drug reactions (ADRs) and adverse drug events (ADEs). PP, IP, ADRs and ADEs in turn cause excessive drug costs and excess ...
Voir le projet

 13

 TERMINÉ 

Resource Preservation by Application of BIOefFECTORs in European Crop Production (BIOFECTOR)

Date du début: 1 sept. 2012, Date de fin: 31 août 2017,

BIOFECTOR is an integrated project that develops alternative fertilisation strategies by the use of various bio-effectors (BEs, plant growth promoting microorganisms and natural extraction products). BEs stimulate root growth, solubilise and mineralise sparingly available nutrients, or protect plants from abiotic and biotic stresses. Novel BEs will be isolated, characterized and applied in strateg ...
Voir le projet

 24

 TERMINÉ 

Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i ...
Voir le projet

 23

 TERMINÉ 

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)

Date du début: 1 oct. 2013, Date de fin: 30 juin 2017,

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus ...
Voir le projet

 15

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet

 29

 TERMINÉ 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet

 17

 TERMINÉ 

Donor T Cells for Immune Control (T-CONTROL)

Date du début: 1 mai 2013, Date de fin: 31 janv. 2017,

Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD). Therefore, this treatment is still associated with a high morbidity a ...
Voir le projet

 6

 TERMINÉ 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 

EUROPEAN FORENSIC GENETICS Network of Excellence (EUROFORGEN-NOE)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

The EUROFORGEN-NoE proposal aims to develop a network of excellence for the creation of a European Virtual Centre of Forensic Genetic Research. Forensic genetics is a highly innovative field of applied science with a strong impact on the security of citizens. However, the genetic methods to identify offenders as well as the creation of national DNA databases have caused concerns to the possible vi ...
Voir le projet

 19

 TERMINÉ 

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease (NILVAD)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet

 17

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects (EUROSKINGRAFT)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the today’s go ...
Voir le projet

 11

 TERMINÉ 

European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults (ENS@T-CANCER)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,

Among patients with adrenal masses Adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavorable prognosis. Due to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which ar ...
Voir le projet

 17

 TERMINÉ 

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Voir le projet

 15

 TERMINÉ 

European Sequencing and Genotyping Infrastructure (ESGI)

Date du début: 1 févr. 2011, Date de fin: 31 juil. 2015,

The objective of this project is the integration of world class high-throughput sequencing and genotyping facilities that will provide sequencing and genotyping technologies and data analysis methodologies to the scientific community.The European Sequencing and Genotyping Infrastructure (ESGI) will enable external users to generate data rapidly and to acquire knowledge efficiently. By providing ac ...
Voir le projet

 11

 TERMINÉ 

Bottom-up reconstitution of a biomimetic bioartificial liver (RE-LIVER)

Date du début: 1 juil. 2012, Date de fin: 30 juin 2015,

The liver, by way of its central role in both endogenous and exogenous metabolism, is one of the most well-studied organs in the human body.Hepatic tissue and its derivatives have a wide range of in-vivo and in-vitro applications from whole organ or partial lobe transplant, bioartificial ex-vivo devices, treatment of metabolic disorders to toxicology, drug metabolism and tissue regeneration. On th ...
Voir le projet

 5

 TERMINÉ 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Date du début: 15 juin 2009, Date de fin: 14 juin 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Voir le projet

 26

 TERMINÉ 

Infectious triggers of chronic autoimmunity (INTRICATE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,

This proposal builds on existing expertise and collaborations of a multidisciplinary Consortium of basic scientists and clinical investigators each of whom has made a substantial individual contribution to understanding the links between infection and autoimmunity. The aim of the INTRICATE Consortium is to prosecute a programme of Translational Research that deliniates the role of infection in the ...
Voir le projet

 13

 TERMINÉ 

Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation (PROCARDIO)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2015,

Epidemiological evidence has established a link between cardiovascular disease and exposure of the heart and major vessels to doses above 500mGy. At lower doses the evidence for a detrimental effect is inconclusive. In part, this is due to the lack of appropriate epidemiological studies, coupled with lack of knowledge of the processes involved that is needed for construction of mathematical models ...
Voir le projet

 15

 TERMINÉ 

Treatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide (NEMO)

Date du début: 1 oct. 2009, Date de fin: 31 mars 2015,

Neonatal hypoxic ischaemic encephalopathy (HIE) occurs in 2-3/1000 live births and is a major cause of both acute mortality and long-term neurodisability. Seizures are the hallmark of HIE. The clinical and electrographic seizure burden in babies with HIE can be considerable and is often not reduced by current antiepileptic drugs. Phenobarbitone remains the first line drug for neonatal seizures des ...
Voir le projet

 15

 TERMINÉ 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Voir le projet

 20

 TERMINÉ 

Developmental Origins of Healthy and Unhealthy Ageing: The Role of Maternal Obesity (DORIAN)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,

Europe has the highest proportion of elderly people in the world. Cardiovascular disease (CVD), type 2 diabetes (T2D), sarcopenia and cognitive decline frequently coexist in the same aged individual, sharing common early risk factors and being mutually reinforcing. Obesity is a main health concern in the world. In the EU one-third of women of reproductive age are overweight and 20% are obese, a pr ...
Voir le projet

 10

 TERMINÉ 

A Treatment-Oriented Research Project of NCL Disorders as a Major Cause of Dementia in Childhood (DEM-CHILD)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2014,

"The DEM-CHILD project focusses on the main cause for childhood dementia in Europe, the neuronal ceroid lipofuscinoses (NCLs). The NCLs are neurodegenerative diseases characterized by dementia, blindness, epilepsy and physical decline leading to an early death of the patients. Since no cure is currently available, these disorders represent a serious social, medical, and economic challenge.To date, ...
Voir le projet

 13

 TERMINÉ 

Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

Date du début: 1 oct. 2009, Date de fin: 31 mars 2014,

"Chronic heart failure (CHF) is a massive clinical, social and economic problem. Diabetes and obesity increase the risk of developing CHF. Cachexia is also an ominous sign. In 13 clinical and preclinical research projects, SICA-HF aims to investigate the impact of these co-morbidities in CHF patients at the clinical, vascular, cellular and molecular levels. SICA-HF will enrol >1600 patients wit ...
Voir le projet

 13